ProfileGDS5678 / 1426813_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 91% 90% 91% 88% 89% 90% 88% 89% 88% 88% 89% 88% 89% 90% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.329791
GSM967853U87-EV human glioblastoma xenograft - Control 27.2740490
GSM967854U87-EV human glioblastoma xenograft - Control 37.4050791
GSM967855U87-EV human glioblastoma xenograft - Control 46.9897588
GSM967856U87-EV human glioblastoma xenograft - Control 57.0369689
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.0659790
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.7069888
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.0347489
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.8395688
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.9270288
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.955189
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.9016388
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.0590589
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.2616490